Early research (Phase 1)Study completedNCT01220648
What this trial is testing
Determining the Maximum Tolerated Dose of Low Dose Interferon-alpha in Conjunction With Nilotinib in Pretreated Philadelphia Chromosome Positive (Ph+) Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP)
Who this might be right for
Chronic Myeloid Leukemia
Novartis Pharmaceuticals 4